Valuation : 4basebio PLC

Market Cap 73.81M 99.8M 85.88M 80.8M 138M 9.42B 138M 955M 370M 4.83B 375M 367M 15.57B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 74.11M 100M 86.22M 81.13M 139M 9.46B 139M 959M 372M 4.85B 376M 368M 15.64B EV / Sales 2026 *
26.5x
EV / Sales 2027 * 8.29x
Free-Float
38.75%
Yield 2026 *
-
Yield 2027 * -
1 day+0.12%
1 week+0.12%
Current month+0.12%
1 month-9.42%
3 months-10.27%
6 months-9.42%
Current year-22.67%
1 week 450
Extreme 450
500
1 month 450
Extreme 450
550
Current year 420
Extreme 420
630
1 year 420
Extreme 420
904.6
3 years 420
Extreme 420
1,820
5 years 390
Extreme 390
1,820
10 years 175
Extreme 175
1,820
Manager TitleAgeSince
Chief Executive Officer 33 10/02/2026
Chief Tech/Sci/R&D Officer - 01/03/2025
Chief Operating Officer - 12/03/2026
Director TitleAgeSince
Director/Board Member 48 22/12/2020
Director/Board Member 33 08/08/2024
Chairman 60 08/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
21/05/26 Buy

Chief Executive Officer

1,863 0.0120%
16/02/26 Buy

Chief Executive Officer

2,650 0.0171%
11/02/26 Buy

Director

3,000 0.0193%
Change 5-day change 1-year change 3-year change Capi.($)
+0.12%+0.12%-44.38%-22.67% 99.8M
-0.95%-2.36%-1.26%+14.34% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
+0.53%-1.36%+16.87%+46.82% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.65%-1.41%+11.89%+30.99% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.72%+0.48%+60.72%+95.39% 27.51B
Weighted average by Cap. -0.78%+0.11%+89.35%+128.87%

Financials

2026 *2027 *
Net sales 2.8M 3.79M 3.26M 3.07M 5.24M 357M 5.25M 36.22M 14.05M 183M 14.22M 13.91M 591M 12M 16.23M 13.96M 13.14M 22.45M 1.53B 22.51M 155M 60.24M 786M 60.93M 59.6M 2.53B
Net income -17.1M -23.12M -19.9M -18.72M -31.99M -2.18B -32.08M -221M -85.84M -1.12B -86.82M -84.93M -3.61B -
Net Debt 300K 406K 349K 328K 561K 38.3M 563K 3.88M 1.51M 19.65M 1.52M 1.49M 63.3M 25.7M 34.75M 29.9M 28.13M 48.08M 3.28B 48.21M 332M 129M 1.68B 130M 128M 5.42B
Logo 4basebio PLC
4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Employees
140
Date Price Change Volume
07/09/26 GBX 475.55 +0.12% 226
04/09/26 GBX 475.00 0.00% 2,102
03/09/26 GBX 475.00 0.00% 10
02/09/26 GBX 475.00 0.00% 425
01/09/26 GBX 475.00 0.00% 652
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.750GBP
Average target price
16.00GBP
Spread / Average Target
+236.84%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!